-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Corning Jereh Biopharmaceuticals announced that it has reached a clinical trial and drug supply cooperation with Pfizer to evaluate the effectiveness and safety of KN046 in combination with Inlead® (axitinib) for the first-line treatment of non-small cell lung cancer (NSCLC) Sex
.
Lung cancer is one of the most threatening malignant tumors to human health and life.
In the past 50 years, many countries have reported that the incidence and mortality of lung cancer have increased significantly
.
National cancer statistics released by the National Cancer Center show that the incidence and mortality of lung cancer account for 20.
Although based on experience, platinum-containing dual chemotherapy is still the gold standard for the treatment of advanced NSCLC without genetic mutations, but there is still a huge unmet clinical need
.
A variety of different concepts in clinical treatment work synergistically, and more and more updated treatment methods and combinations are constantly being explored to improve the prognosis and quality of life of patients
KN046 is a bispecific antibody that targets both PD-L1 and CTLA-4 immune checkpoints.
It can more effectively activate T cells and enhance immune anti-tumor ability
.
KN046 Phase II clinical study data for advanced non-small cell lung cancer showed good tolerability and safety, as well as the advantages of PFS and OS
The combination drug will first carry out a multi-center, open-label Phase II clinical study to evaluate the effectiveness, safety and tolerability of KN046 combined with axitinib in the treatment of patients with advanced non-small cell lung cancer
.
Professor Zhang Li from the Cancer Hospital of Sun Yat-sen University served as the main investigator.
Dr.
Xu Ting, Chairman and President of Corning Jerry, said: “KN046 is the world’s leading PD-L1/CTLA-4 bispecific antibody.
We strive to quickly promote its clinical development and marketing layout.
At the same time, we are very happy to cooperate with Pfizer.
The company once again cooperates.
Their deep accumulation in the field of cancer and expertise in drug development will help us fully develop the potential of KN046 for the treatment of patients with advanced lung cancer.
It is hoped that this cooperation will produce a new therapeutic combination to solve Unmet clinical needs in this field serve patients worldwide
.
"
